中山康方生物医药有限公司

Chinese biopharmaceutical company founded in 2012 and based in Zhongshan, Guangdong, whose holding company is listed on the Hong Kong Stock Exchange under code 9926. Discovers, develops, manufactures and commercialises antibody therapeutics for cancer, autoimmune disease, inflammation and metabolic disease, and is known for bispecific antibodies including the PD-1 and CTLA-4 bispecific cadonilimab and the PD-1 and VEGF bispecific ivonescimab. Runs an integrated platform covering antibody discovery, process development, clinical development and commercial manufacturing at its own facility in Zhongshan, and has licensed programmes to international partners.